US (858) 956-1200 info@www.genalyte.com

About

We deliver diagnostic data when it’s needed–when the patient is with the doctor

 

Leadership

Our leadership team draws on diverse backgrounds spanning healthcare and technology.

Ashraf Hanna, MD PhD

CEO

Ashraf Hanna is the Chief Executive Officer of Genalyte.

Previously he was the COO of Verily Life Sciences, an Alphabet company focused on leveraging data to improve healthcare outcomes, accessibility and cost. Prior to Verily, he was the CEO of ORIC Pharmaceuticals, a company developing treatments for cancer resistance, and before that, Ashraf spent nearly 11 years as a Vice President at Genentech leading the Commercial and Medical Affairs Finance functions, as well as Alliance Management and Portfolio Planning group, which is responsible for developing product plans, metrics and guiding R&D investments. Ashraf was also the CFO for the Genentech foundation, and previously at McKinsey and Company. He has a has a Ph.D. in Physics from Harvard University, an M.D. from the University of Massachusetts, and was an undergraduate at the University of Chicago.

CARy Gunn, PhD

Founder

Dr. Cary Gunn — who drives Genalyte’s strategic vision, direction, culture and success — has been blazing trails in the technology community for almost 30 years.

Prior to leading Genalyte, Cary served as co-founder and chief technical officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in applied physics and organic chemistry from the United States Air Force Academy and his PhD in electrical engineering from the California Institute of Technology (Caltech). At Genalyte, Cary is proud to pioneer technology that has “a positive impact on life and human health.”

Hossein Fakhrai-Rad, PhD

 President and CSO, BaseHealth Analytics

Hossein is an experienced entrepreneur who has worked on developing various technologies and models for identification and characterization of numerous risk factors for common complex diseases for the past 20 years.

His latest startup BaseHealth which was founded by him in 2011, was a predictive
health analytics company that empowered leading health systems and Medicare Advantage plans to
maximize revenues, cost-savings and clinical outcomes through a proprietary machine learning and
artificial intelligence platform that was built on the most diverse and comprehensive set of data types in
the industry. Prior to that, Hossein was a founding member of ParAllele Bioscience, a startup company
that developed 2 main technologies for identification and scanning of genetic variations. ParAllele was
then acquired by Affymetrix, when Hossein took the lead of building and managing the Affymetrix’s
Genetic service lab.
Hossein earned his PhD in Medical Genetics from the Karolinska Institute in Sweden and completed his
post-Doctoral fellowship at Stanford Genome Technology Center. He has written over 20 peer-reviewed
publications in Journals and books and holds number of pending and issued patents.

RICK HOCKETT, MD

CMO

A clinical pathologist certified by the American Board of Pathology, Chief Medical Officer Rick Hockett is the mind behind Genalyte’s clinical strategy, development and operations.

He also oversees daily operations of our CLIA laboratory and 510(k) submission of our proprietary diagnostic instrumentation and assays for regulatory approval. Rick has spent three decades applying biomarkers to clinical medicine, distinguishing him as a leader in personalized medicine. Among many professional achievements, Rick was responsible for the first standalone genetic component for a New Drug Application to the U.S. Food and Drug Administration. Rick maintains active medical licenses in Indiana, California, New York and Colorado. He earned his bachelor’s degree in chemistry at the University of South Dakota and his doctorate of medicine from the University of Minnesota; he completed his residency in clinical pathology at Washington University, St. Louis. He is inspired by Genalyte’s mission to empower medical practitioners and patients through tech.

Prakash Menon

CTO, BaseHealth Analytics

Prakash has always been intrigued by the promise of data based medical care and in particular it’s role in moving to a more prevention-based paradigm.

In a long career in software development, he has helped build patient management and hospital management systems on multiple continents. Most recently he had executive leadership responsibilities at Hara Software, a KPCB backed startup that defined and lead the market in the energy management. Prior to that he spent more than a decade at Oracle, working with and leading teams that built, among other things, cutting edge performance management solutions for distributed Enterprise applications. Prakash holds a bachelor’s degree in Engineering and a master’s degree in business.

Elisa Romeo, PHD

SVP, Operations

Dr. Elisa Romeo oversees Operations at Genalyte to ensure our products are designed, developed, and manufactured with the utmost quality.

She joined Genalyte in 2020 bringing her expertise in diagnostic test development for CLIA-certified, CAP-accredited commercial laboratories and medical device companies focused on in vitro diagnostic test development. Dr. Romeo has experience leading quality and regulatory functions as well as medical device manufacturing. Prior to joining Genalyte, Dr. Romeo was COO at Drawbridge Health and VP of Research and Development at Gensignia Life Sciences. She received her MS in Molecular Biology from the University of Insubria (Italy) and she earned a PhD in Biochemistry and Human Physiology from the University of Zurich (Switzerland).

Madonna Moreno

Director, Human Resources

A 19-year veteran of her field, Madonna Moreno can be credited with shaping Genalyte’s innovative, dynamic culture by dictating company values and people strategy.

She is responsible Genalyte’s human resources functions including talent management, employee development, benefits, compensation, and business support. A leader in her field, Moreno is president of the San Diego Life Sciences HR Network, a nonprofit organization dedicated to developing innovation and strategic human resources practices in life sciences industries. Moreno is a Certified Professional in Human Resources and a Society for Human Resources Certified Professional. Moreno holds a bachelor’s degree in political science and a master’s in business administration, both from the University of San Diego. Having spent 11 years in biotechnology and life sciences companies — including Trovagene and the Salk Institute for Biological Studies — Moreno is passionate about working with innovative thinkers, and connecting talented people with meaningful opportunities to impact health and change lives.

SASI MUDUMBA, PHD

VP, Assay Development

Dr. Sasi Mudumba oversees the research, development, validation, regulatory submission and approval of the diagnostic assays at the heart of Genalyte’s revolutionary technology.

She has spent more than 20 years in research, development and commercialization in life sciences, drug discovery and medical devices. Mudumba has guided several In Vitro Diagnostics (IVD) products through approvals at federal agencies including the Food and Drug Administration and Health Canada, and was responsible for leading a multiplexed autoimmune IVD assay on microarray technology from development to regulatory approval. Her previous roles include Director of Assay Development at Regulatory Affairs at SQI Diagnostics and Senior Scientist at NoAb BioDiscoveries. Mudumba earned her bachelor’s degree in microbiology at Osmania University before obtaining her master’s degree in biochemistry from the Unviersity of Hyderabad; her PhD in biotechnology is from Jawaharlal Nehru Technological University. At Genalyte, she is excited to work with technology that speeds the diagnosis and treatment of autoimmune diseases.

Michael O’Neil

VP, Product Marketing

Michael leads Genalyte’s strategic direction by reading the market, identifying key market segments and designing innovative products and services to meet those needs.

Among his proudest career moments, O’Neil spearheaded the design and implementation of one of the first accountable care organizations in the country while serving as Senior Director of Product Innovation at Blue Shield of California. Improving quality of healthcare while cutting costs by almost $38 million in two years, the ACO model has been replicated by more than 32 medical groups and hospitals across the state. He earned his bachelor’s degree in political science from Dartmouth College and a master’s degree in education from Stanford University. With 20 years in the healthcare industry under his belt, O’Neil is inspired by Genalyte’s mission to improve patient-provider interactions with real-time data, and he’s proud to be part of bettering the lives of his friends, family and community.

Board of Directors

ASHRAF HANNA, MD PHD

CEO

Ashraf Hanna is the Chief Executive Officer of Genalyte.

Previously he was the COO of Verily Life Sciences, an Alphabet company focused on leveraging data to improve healthcare outcomes, accessibility and cost. Prior to Verily, he was the CEO of ORIC Pharmaceuticals, a company developing treatments for cancer resistance, and before that, Ashraf spent nearly 11 years as a Vice President at Genentech leading the Commercial and Medical Affairs Finance functions, as well as Alliance Management and Portfolio Planning group, which is responsible for developing product plans, metrics and guiding R&D investments. Ashraf was also the CFO for the Genentech foundation, and previously at McKinsey and Company. He has a has a Ph.D. in Physics from Harvard University, an M.D. from the University of Massachusetts, and was an undergraduate at the University of Chicago.

Cary Gunn, Phd

Founder

Dr. Cary Gunn — who drives Genalyte’s strategic vision, direction, culture and success — has been blazing trails in the technology community for almost 30 years.

Prior to leading Genalyte, Cary served as co-founder and chief technical officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in applied physics and organic chemistry from the United States Air Force Academy and his PhD in electrical engineering from the California Institute of Technology (Caltech). At Genalyte, Cary is proud to pioneer technology that has “a positive impact on life and human health.”

Gerard van hamel Platerink

Member, Board of Directors

Gerard joined Redmile as a managing director in May 2012.

Prior to working with Redmile, Gerard was a Managing Director with Accuitive Medical Ventures (AMV).  AMV II has recently been ranked in the top quartile of healthcare VC funds for its vintage year (Source: Cambridge Assoc.).  Gerard has cofounded a number of healthcare companies including Halscion, Sebacia and First Aid Shot Therapeutics.  In addition, Gerard led AMV’s investments in Axogen (public: AXGN), Cardiofocus, Neuronetics and Intuity Medical.  Before AMV, Gerard worked with Novoste Corporation, the cardiology technology company, in business development and corporate communications. Before joining Novoste, Gerard was an equity research analyst with Salomon Brothers (now Citigroup) in London, where he was a member of the top ranked European healthcare research team.  Gerard began his career with Kleinwort Benson, where he was an investment banker and member of the bank’s private equity and mezzanine finance group. Gerard is a Dutch national, was born in Borneo in Southeast Asia, grew up in Africa and was educated in the UK where he got his BS in Physics (1st Class Honors) from St. Andrews University and an MBA from Cambridge University.

Saeid Akhtari

        Member, Board of Directors

Saeid is the Managing Director at HBM Genomics investing in world-class entrepreneurs in life sciences companies.

He has more than 25 years of experience as an entrepreneur building successful biotech companies from scratch. Saeid is an active investor/advisor in leading life sciences companies, including Genalyte, Clear Labs, Convergent Genomics, Encoded Therapeutics, Haystack Biosciences, Seer Biosciences, Trace Genomics, and Xcell Biosciences.

Prior to HBM Genomics, Saeid was the founder, President & CEO of NextBio which was acquired by Illumina in 2013. Prior to founding NextBio, he was the President & CEO of Silicon Genetics which was acquired by Agilent in 2004. Mr. Akhtari has also held executive management positions at several other life sciences companies.

Jeff Huber

         Member, Board of Directors

Jeff Huber is the Founding CEO and Vice Chairman of GRAIL (2016-present). GRAIL's mission is to detect cancer early, when it can be cured.

Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google’s life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.

Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology, including Openwater, Mammoth Biosciences, Vir, Sana, Zymergen, Atomwise, Genalyte, Pinterest, Honor, OpenDoor, and AngelList.

Jeff holds a bachelor’s degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a ‘Distinguished Alumni Award’ from the College of Electrical & Computer Engineering (2018) for ‘challenging the status quo through innovation’. He also holds a master’s degree in business from Harvard University. Jeff is a board member of GRAIL (Vice Chairman), Genalyte (Chairman), Electronic Arts (EA), Openwater, and The Exploratorium, and a former board member of Illumina (ILMN; 2014-2016).

 

Joe Markee

       Member, Board of Directors

Joe Markee Managing Director at Express Ventures

Joe brings extensive experience in early stage company formation, capital raising, corporate management, and public and private corporate governance. Joe’s startup experience encompasses Primary Access as a founder and senior manager, Copper Mountain Networks as founding CEO, CTO and Chairman, Figure 8 Wireless as CEO and StackIQ as CEO and Chairman.

Joe was also a founder and served as President of the San Diego Telecommunications Council (renamed CommNexus). He has been honored with awards for his contributions to San Diego’s high-tech business community, including Master Entrepreneur.

Investors

A blog about Wordpress design, development , Software and inspiration http://themesharebd.blogspot.com